Blood Advances · 2022 · 20 citations · 36 references
Life SciencesGeneticsHematologyClinical ImmunologyImmunogeneticsImmunopathologyHuman Leukocyte Antigen SystemImmune Repertoire FormationImmunogenomicsImmunoglobulin DisordersImmunoglobulin DiversityImmunoglobulin Gene RearrangementAntibody Repertoire AnalysisGene Rearrangement AnalysisGermline Antibody RepertoireGermline Immunoglobulin Gene UsageHeavy Chain DiversityImmunoglobulin Heavy Chain RearrangementImmunoglobulin Light Chain RearrangementLymphoplasmacytic Lymphoma
Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) is a heterogeneous disease in which the role of immunoglobulin heavy-chain genes (IGHs) remains unknown. To determine the clinical relevance of the IGH repertoire in patients with LPL/WM, we performed immunoglobulin gene rearrangement and complementarity determining region 3 (CDR3) analysis. The IGH variable gene (IGHV) repertoire was remarkably biased in LPL/WM. IGHV3-23, IGHV4-34, IGHV3-30, IGHV3-7, and IGHV3-74 accounted for one-half of the cohort's repertoire. Most cases (97.1%) were found to carry mutated IGHV genes, based on a 98% IGHV germline homology cutoff. IGHV3-30 was associated with long heavy chain CDR3, indicating there was specific antigen selection in LPL/WM. Patients with IGHV3-7 were significantly more likely to harbor the 6q deletion (P < .001) and an abnormal karyotype (P = .004). The IGHV hypermutation rate in patients with the MYD88 L265P mutation was significantly higher than that of wild-type patients (P = .050). IGHV3-23 and IGHV3-74 segments were more frequently detected in patients with MYD88-mutated LPL/WM (P = .050), whereas IGHV3-7 presented more frequently in MYD88 wild-type patients (P = .042). Patients with IGHV4, especially IGHV4-34, had higher levels of lactate dehydrogenase, and IGHV4 was a predictive marker of shorter progression-free survival. These results showed for the first time that the IGHV repertoire has clinical relevance in LPL/WM.
36
International prognostic scoring system for Waldenström macroglobulinemia
Pierre Morel, Alain Duhamel, Paolo G. Gobbi et al. · Blood · 2009 · 413 citations · Full text
How I treat Waldenström macroglobulinemia
Steven P. Treon · Blood · 2015 · 287 citations · Full text
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Stéphanie Poulain, Christophe Roumier, Audrey Decambron et al. · Blood · 2013 · 231 citations · Full text